FDA 483 - Mary Kay, Inc - July 19, 2019

An FDA inspection of Mary Kay, Inc.'s OTC drug facility in Dallas, TX, revealed three significant observations. These included failures in preventing contamination during component handling and storage, inadequate visual examination of incoming component containers for damage, and deficient procedures for equipment cleaning and maintenance. The findings indicate issues with quality control and adherence to good manufacturing practices.